Zobrazeno 1 - 10
of 1 814
pro vyhledávání: '"rho kinase inhibitor"'
Autor:
Élodie Reboussin, Paul Bastelica, Ilyes Benmessabih, Arnaud Cordovilla, Cécile Delarasse, Annabelle Réaux-Le Goazigo, Françoise Brignole-Baudouin, Céline Olmière, Christophe Baudouin, Juliette Buffault, Stéphane Mélik Parsadaniantz
Publikováno v:
Acta Neuropathologica Communications, Vol 12, Iss 1, Pp 1-21 (2024)
Abstract Background Glaucoma is a leading cause of blindness, affecting retinal ganglion cells (RGCs) and their axons. By 2040, it is likely to affect 110 million people. Neuroinflammation, specifically through the release of proinflammatory cytokine
Externí odkaz:
https://doaj.org/article/78539926c1e24f9ea37b32a906073d74
Publikováno v:
Taiwan Journal of Ophthalmology, Vol 14, Iss 1, Pp 88-94 (2024)
PURPOSE: This study aimed to evaluate the efficacy of ripasudil in managing various corneal edema conditions. MATERIALS AND METHODS: This single-center retrospective analysis was conducted at Hadassah Medical Center and involved 16 patients with 17 e
Externí odkaz:
https://doaj.org/article/9924ae7f6c5e4585ae1922449cc97d9d
Autor:
David Wirta, MD, Xiao-Yan Li, MD, Wang Shen, PhD, Caroline Lu, MS, Gary D. Novack, PhD, William Christie, MD, Paul J. Hartman, MD, Lawrence Tafoya, MD, PhD, Navin Tekwani, MD
Publikováno v:
Ophthalmology Science, Vol 4, Iss 2, Pp 100426- (2024)
Purpose: To assess safety and ocular hypotensive efficacy of VVN539 ophthalmic solution in a first-in-human study. Design: Multicenter, double-masked, randomized, vehicle-controlled, dose-response, parallel-comparison study. Participants: Sixty-eight
Externí odkaz:
https://doaj.org/article/dd843ed5dee24a18aff6fd4d9405beb5
Autor:
Ryoji Yanai, Sho-Hei Uchi, Masaaki Kobayashi, Tomohiko Nagai, Shinichiro Teranishi, Makiko Wakuta, Kazuhiro Kimura
Publikováno v:
International Journal of Ophthalmology, Vol 16, Iss 6, Pp 904-908 (2023)
AIM: To investigate the efficacy of ripasudil, a Rho kinase inhibitor, in reducing intraocular pressure (IOP) and medication scores of anti-glaucoma drugs in patients with ocular hypertension with inflammation and corticosteroid. METHODS: The study i
Externí odkaz:
https://doaj.org/article/631f275e6e0a4260a212831b6f9e77cd
Publikováno v:
Indian Journal of Ophthalmology, Vol 71, Iss 7, Pp 2756-2759 (2023)
Purpose: Ripasudil is a class of drug which alters the trabecular meshwork to increase the aqueous outflow and has been shown to be effective in pseudoexfoliative glaucoma (PXF G). This study aimed at assessing the efficacy and safety profile of ripa
Externí odkaz:
https://doaj.org/article/7c78ef60e13d49cf891a8834bffbab41
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Guoji Yanke Zazhi, Vol 22, Iss 9, Pp 1441-1445 (2022)
AIM:To investigate the influence of K-115 on the proliferation and migration of human Tenon's fibroblasts(HTFs)and to access the possible mechanism. Furthermore, to provide new ideas for anti-scar treatment after glaucoma surgery.METHODS: The Tenon c
Externí odkaz:
https://doaj.org/article/7ceefa4be6854e8ea5b1c3ae326dba71
Publikováno v:
Indian Journal of Ophthalmology, Vol 70, Iss 6, Pp 2020-2023 (2022)
Purpose: Ripasudil hydrochloride hydrate (0.4%) is the first Rho-associated protein kinase (ROCK) inhibitor eye drop that lowers intraocular pressure (IOP) by increasing conventional aqueous outflow through the trabecular meshwork and Schlemm's canal
Externí odkaz:
https://doaj.org/article/952e859e71d44d17b2fb5c18c40ec464
Publikováno v:
Neural Regeneration Research, Vol 17, Iss 12, Pp 2623-2631 (2022)
Ras homolog (Rho)-associated kinases (ROCKs) belong to the serine-threonine kinase family, which plays a pivotal role in regulating the damage, survival, axon guidance, and regeneration of neurons. ROCKs are also involved in the biological effects of
Externí odkaz:
https://doaj.org/article/8fde7ae105ca49a4b5499c0613b60fd5
Autor:
Alex T. Pham, BS, Chris Bradley, PhD, Corinne Casey, OD, Henry D. Jampel, MD, Pradeep Y. Ramulu, MD, PhD, Jithin Yohannan, MD, MPH
Publikováno v:
Current Therapeutic Research, Vol 98, Iss , Pp 100689- (2023)
ABSTRACT: Background: Rho kinase inhibitors, such as netarsudil, are a relatively new class of medications recently introduced into the market for the treatment of glaucoma, the leading cause of irreversible blindness in the world. Previous clinical
Externí odkaz:
https://doaj.org/article/78545bddeff740ceb58e0243213ba967